FWDI

Forward Industries, Inc. - 10-Q Summary (Period Ended June 30, 2009)

Business Context and Reporting Period

Forward Industries, Inc. designs, markets, and distributes custom soft-sided carrying cases for portable electronic devices, primarily blood glucose monitoring kits for diabetic patients. The company sells directly to Original Equipment Manufacturers (OEMs) in the Americas, APAC, and Europe. This report covers the quarterly period ended June 30, 2009 (2009 Quarter) and the nine-month period ended June 30, 2009 (2009 Period). The company is classified as a smaller reporting company.

Key Financial Metrics

Liquidity: The company reported a current ratio of 14.2 and a quick ratio of 13.7 as of June 30, 2009. There is no short-term or long-term debt outstanding. A Swiss subsidiary maintains an uncommitted credit line of $400,000, with a $315,000 letter of credit outstanding, reducing available capacity.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 26% ($1.46 million) in the 2009 Quarter and 10% ($1.58 million) in the 2009 Period compared to the prior year periods. The decline was driven primarily by a 30% drop in diabetic product sales in the quarter and an 11% drop in the nine-month period, largely due to lower volumes and pricing from the company's largest customer.
• Profitability: While net loss narrowed slightly in the quarter ($64k vs $111k loss), the nine-month net loss widened significantly ($1.32 million vs $0.76 million loss). The widening nine-month loss was primarily due to a $0.3 million income tax provision resulting from the establishment of a full valuation allowance against deferred tax assets, compared to a tax benefit in the prior year.
• Expense Reduction: Operating expenses decreased 13% in the quarter and 12% in the nine-month period, driven by lower royalty expenses (following a license amendment with Motorola), reduced professional fees, and personnel cost reductions.
• Cash Flow: Operating cash flow turned negative, using $0.18 million in the nine-month period compared to generating $0.04 million in the prior year. This was due to the net loss and a $0.7 million decrease in accounts payable, partially offset by reductions in inventory and accounts receivable.

Outlook, Risks, and Management Commentary

• Economic Environment: Management cites deteriorating global economic conditions, rising unemployment, and tight credit markets as adverse factors impacting consumer spending and OEM demand.
• Customer Concentration Risk: Approximately 75% of sales are concentrated in the diabetic product line, with high dependence on a few large OEM customers. Variability in order flow from these customers creates significant revenue volatility.
• "In-Box" Model Risk: A critical risk is the potential for OEM customers to reduce or eliminate "in-box" accessory models or switch to lower-cost, universal carry solutions to reduce their own expenses. This trend could materially and adversely affect revenue and gross margins.
• Inventory and Tax: The company established a full valuation allowance of approximately $0.5 million against its deferred tax assets due to cumulative losses and uncertainty regarding future taxable income. Inventory allowances were reduced to $64,000 from $168,000 in the prior year.
• Guidance: The filing does not provide specific numerical guidance for future periods but anticipates that the challenging business environment will continue in the foreseeable future.

Investor Verification Checklist

• Customer Concentration: Verify the specific impact of the largest diabetic product customer's volume and pricing changes on future quarters.
• OEM Strategy Shifts: Monitor announcements from key OEM customers regarding changes to "in-box" accessory packaging or cost-reduction initiatives.
• Deferred Tax Assets: Assess the likelihood of the company reversing the full valuation allowance on deferred tax assets if profitability improves.
• Working Capital Trends: Track the continued reduction in accounts payable and inventory to ensure it reflects sales volume rather than supply chain disruptions.
• Foreign Earnings: Review the status of the $3.9 million in undistributed earnings held by the Swiss subsidiary and any potential tax implications of repatriation.